Press Release Details

Cerus Announces Agreement with the National Transfusiology Center of Mongolia for the Use of INTERCEPT Platelets and Plasma

December, 10 2015

CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (NASDAQ: CERS) announced today that the National Transfusiology Center (NTC) of Mongolia has signed a purchase agreement for the INTERCEPT Blood System for platelets and plasma. The agreement is part of a national tender awarded to Cerus’ Mongolian distributor, Inter Science LLC, for the supply of blood bank equipment.

“We are honored that INTERCEPT has been chosen by the National Transfusiology Center of Mongolia as part of an important initiative to improve blood transfusion safety,” commented Pascal Maillard, Cerus’ Vice President for Asia. “INTERCEPT’s pathogen inactivation technology represents a leap forward for patients receiving care through the Mongolian health care system.”

The NTC aims to improve the safety of individuals working in and receiving care through the Mongolian health care system, with a mission to improve the safety of blood transfusions, strengthen medical waste management, and prevent and control hospital acquired infections. Mongolia has one of the highest rates of hepatitis B and C in the world, with insufficient blood transfusion and waste management practices contributing to additional rates of infection.

The NTC will complete several system and equipment modifications through 2017 as part of the Fifth Health Sector Development Project (FifHSDP), a partnership between the Ministry of Health and Sports of Mongolia and the Asian Development Bank to technologically improve health care facilities across Mongolia.


Cerus Corporation is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as Hepatitis B and C, HIV, West Nile Virus and bacteria, as well as emerging pathogens such as chikungunya, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development. See for information about Cerus.

INTERCEPT and INTERCEPT Blood System are trademarks of Cerus Corporation.

Source: Cerus Corporation

Cerus Corporation

Stacey Leanos - Associate Director, Investor & Public Relations

Lainie Corten - Vice President, Global Marketing & Investor Relations

(925) 288- 6137

    Global Headquarters

  • 1220 Concord Avenue
  • Concord, CA US 94520
  • +1 925.288.6000

    European Headquarters

  • Stationsstraat 79-D
  • 3811 MH Amersfoort, Netherlands
  • +31 (0) 33 49 60 600